CA2610366A1 - Selective apoptotic induction in cancer cells including activation of procaspase-3 - Google Patents

Selective apoptotic induction in cancer cells including activation of procaspase-3 Download PDF

Info

Publication number
CA2610366A1
CA2610366A1 CA002610366A CA2610366A CA2610366A1 CA 2610366 A1 CA2610366 A1 CA 2610366A1 CA 002610366 A CA002610366 A CA 002610366A CA 2610366 A CA2610366 A CA 2610366A CA 2610366 A1 CA2610366 A1 CA 2610366A1
Authority
CA
Canada
Prior art keywords
procaspase
compound
pac
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002610366A
Other languages
English (en)
French (fr)
Inventor
Paul J. Hergenrother
Karson S. Putt
Grace W. Chen
Jennifer M. Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2610366A1 publication Critical patent/CA2610366A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CA002610366A 2005-05-26 2006-05-26 Selective apoptotic induction in cancer cells including activation of procaspase-3 Abandoned CA2610366A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68480705P 2005-05-26 2005-05-26
US60/684,807 2005-05-26
US74387806P 2006-03-28 2006-03-28
US60/743,878 2006-03-28
US11/420,425 2006-05-25
US11/420,425 US20070049602A1 (en) 2005-05-26 2006-05-25 Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
PCT/US2006/020910 WO2006128173A2 (en) 2005-05-26 2006-05-26 Selective apoptotic induction in cancer cells including activation of procaspase-3

Publications (1)

Publication Number Publication Date
CA2610366A1 true CA2610366A1 (en) 2006-11-30

Family

ID=37452994

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002610366A Abandoned CA2610366A1 (en) 2005-05-26 2006-05-26 Selective apoptotic induction in cancer cells including activation of procaspase-3

Country Status (10)

Country Link
US (1) US20070049602A1 (enExample)
EP (3) EP2634581A1 (enExample)
JP (2) JP5513741B2 (enExample)
AU (1) AU2006251978A1 (enExample)
CA (1) CA2610366A1 (enExample)
DK (1) DK1893210T3 (enExample)
ES (1) ES2763156T3 (enExample)
IL (1) IL187603A0 (enExample)
MX (1) MX2007014843A (enExample)
WO (1) WO2006128173A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) * 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
WO2010091382A1 (en) 2009-02-09 2010-08-12 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
WO2010102513A1 (zh) * 2009-03-11 2010-09-16 深圳市湘雅生物医药研究院 高哌嗪乙酰肼类衍生物及其制备方法和用途
CN101805338B (zh) * 2010-04-06 2014-10-15 沈阳药科大学 噁二唑基哌嗪衍生物及其用途
US8916705B2 (en) * 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
EP2819661B1 (en) 2012-03-02 2016-11-09 The Board of Trustees of the University of Illionis Potent anticancer activity via dual compound activation
MX365392B (es) * 2012-03-06 2019-05-31 Univ Illinois Composición de combinación de pac-1 y doxorrubicina.
JP6222608B2 (ja) * 2012-03-06 2017-11-01 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 膠芽腫のためのプロカスパーゼ併用療法
US9249116B2 (en) * 2012-08-03 2016-02-02 The Board Of Trustees Of The University Of Illinois Enzyme-activating compounds and compositions
CN105218399B (zh) 2014-05-30 2018-02-09 中国人民解放军军事医学科学院毒物药物研究所 一种取代乙酰肼类衍生物、其制备方法及用途
WO2016197129A1 (en) 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
EP3326631B1 (en) * 2015-07-23 2021-07-14 Zhimin Wang Compound pac-1 or salt thereof, and pharmaceutical composition comprising same
WO2017015784A1 (zh) * 2015-07-24 2017-02-02 深圳市湘雅生物医药研究院 奥比特嗪-富马酸盐、水合物、晶型及其制备方法
CN105085421B (zh) * 2015-07-24 2017-12-26 深圳市湘雅生物医药研究院 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
AU2018368453B2 (en) * 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
KR20210084442A (ko) 2018-10-05 2021-07-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 포도막 흑색종 치료를 위한 병용 요법
WO2025129066A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of California Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4068666B2 (ja) * 1997-05-22 2008-03-26 ザ バーナム インスティチュート カスパーゼ活性のアポトーシスインヒビター（ｉａｐ）タンパク質調節を変える薬剤についてのスクリーニングアッセイ
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
AU5205499A (en) 1998-07-27 2000-02-21 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
KR100439425B1 (ko) * 2001-03-22 2004-07-05 (주)바이오케어 잔토리졸을 포함하는 조성물 및 그 용도
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
CA2508690A1 (en) * 2002-12-10 2004-06-24 Ottawa Health Research Institute Modulation of stem cell differentiation by modulation of caspase-3 activity
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3

Also Published As

Publication number Publication date
MX2007014843A (es) 2008-02-14
AU2006251978A1 (en) 2006-11-30
EP2634581A1 (en) 2013-09-04
EP1893210A4 (en) 2010-09-01
JP5907852B2 (ja) 2016-04-26
WO2006128173A3 (en) 2007-05-24
WO2006128173A2 (en) 2006-11-30
DK1893210T3 (da) 2020-01-13
EP2659884A3 (en) 2014-10-01
EP1893210B1 (en) 2019-10-02
EP1893210A2 (en) 2008-03-05
JP5513741B2 (ja) 2014-06-04
US20070049602A1 (en) 2007-03-01
ES2763156T3 (es) 2020-05-27
JP2008545718A (ja) 2008-12-18
IL187603A0 (en) 2008-03-20
JP2013100285A (ja) 2013-05-23
EP2659884A2 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
US11612598B2 (en) Compounds and methods for the treatment of cancer
JP5907852B2 (ja) プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導
Agarwal et al. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells
US11325892B2 (en) Compounds and methods for treating cancer
Yuan et al. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
JP5655213B2 (ja) Ｋ−Ｒａｓ突然変異性癌疾患治療剤のスクリーニング方法
Schimmer et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy
Cacciatore et al. Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
Markowitz et al. Design of Inhibitors for S100B
Draganov et al. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs
CN101184491A (zh) 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
Cao et al. Synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp/ABCB1) inhibitors for reversing multidrug resistance
Sriratanasak et al. Novel c-Myc–targeting compound N, N-Bis (5-ethyl-2-hydroxybenzyl) methylamine for mediated c-Myc ubiquitin-proteasomal degradation in lung cancer cells
Xiong et al. Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors
Romagnoli et al. Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents
Wang et al. Novel thiohydantoin analogues bearing the 1-hydroxyl-2, 2, 2-trifluoro-1-ethyl moiety as androgen receptor inhibitors for the potential treatment of castration resistant prostate cancer
US20110172311A1 (en) Compounds For Treating Human Papillomavirus
KR101400505B1 (ko) Ｐ５３ 기능을 대체하거나 작동시키는 소형 분자
CN118994135B (zh) 具有芳基酰胺结构的化合物及其医药用途
US8487131B2 (en) Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
WO2013019655A2 (en) Vimentin as a biomarker for the progression of myeloproliferative neoplasms
Alghamdi et al. Design, synthesis and anticancer evaluation of naphthalen-1-yloxyacetamide derivatives against MCF-7 cells
Abdullayeva et al. A novel benzamide derivative SY-15 inhibits multiple myeloma cell proliferation
KR20230058258A (ko) Uch37 탐지용 프로브 및 이의 용도

Legal Events

Date Code Title Description
FZDE Discontinued